Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    NIAID Contract to Medigen for Influenza Virus-Like Particles

    By Global Biodefense StaffJuly 2, 2013
    Share
    Facebook LinkedIn Reddit Email

    Virus ParticlesThe National Institute of Allergy and Infectious Diseases (NIAID) this week announced intentions to procure laboratory testing services to produce, purify, and quantify viral-like particles (VLPs) from Medigen, Inc. on a sole source basis.

    Medigen will provide all the necessary reagents, equipment and personnel with expertise to perform the planned experiments necessary to produce six highly purified influenza VLPs specific to sequences of the influenza plasmids supplied by NIAID.

    NIAID states the contractor will produce 1-5mg purified influenza VLPs by performing:

    High-titer baculovirus stocks from the six influenza plasma provided by NIAID
    Production and harvest six lots of VLPs in serum free medium from SF9 cells
    Purification of six VLPS to greater than 80% purity with the techniques to be employed that will be either tangential flow filtration and or affinity chromatography
    Quality control assessment of protein content using bicinchoninic acid assays or SDS polyacrylamide gel electrophoresis
    Epitope confirmation using western blot and electron microscopy
    Hemagglutination assays

    The performance period is six months from the date of award. Work will be performed in Bethesda, Maryland.

    Source: FBO.gov

    Awards Influenza
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBooz Allen to Lead DTRA’S POC Diagnostic Grand Challenge
    Next Article Army Seeks Characterization of Alphavirus Countermeasure Candidates

    Related Stories

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023

    COVID Moonshot Consortium Announces Crowd-Sourced Small Molecule Discovery

    November 11, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Dec 5
    10:45 am - 3:00 pm EST

    Meeting the Moment: Biodefense Policy, Procurement, and Public Health

    Dec 6
    Virtual Event Virtual Event
    6:00 am - 7:00 am EST

    AMR One Health Priority Research Agenda: Transmission

    Mar 12
    Virtual Event Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.